Curis preclinical data

In animal models of NHL, twice-daily 50 mg/kg oral CUDC-907 for 5 days per week reduced tumor growth vs. vehicle-treated controls. CUDC-907 is a dual phosphoinositide 3-kinase (PI3K) and histone dea...